Article Sidebar

Download
PDF

Main Article Content

Abstract

 
ABSTRACT
Background. Benign prostatic hypertrophy (BPH) is a common disorder and most common cause of morbidity in ageing men. The evaluation of lower urinary symptoms (LUTS) and the bother associated with it are important for management. The International Prostate Scoring System (IPSS), the quality of life score (QoL) due to urinary symptoms are practiced to quantify the severity of LUTS. Objective. To find the correlation between the prostate volume and LUTS based on the IPSS score in patients with histologic BPH. Methods. This was a retrospective study from March 2020 to March 2021 at the Nkwen Baptist Hospital. A total of 45 patients were included, age ranged from 40 to 90 years, with histologic confirmation of BPH and a documented IPSS and prostate volume. Data were analysed using SPSS version 26.0, and p value < 0.05 was considered statistically significant. Results. The mean age was 69.89±7.526 years range 40 to 90 years. Most of the patients had moderate symptoms (66.7%) with mean IPSS value of 17.84±5.661. There was a moderate positive significant correlation between prostate volume and IPSS (r=0.0410, p=0.006) and no significant correlation between prostate volume and QoL. Conclusion. This study showed that there is significant correlation between prostate volume and the IPSS score due to BPH and no significant correlation between the QoL score due to LUTS and transrectal ultrasound calculated prostate volume.
RÉSUMÉ
Introduction. L'hypertrophie bénigne de la prostate (HBP) est un trouble courant et la cause la plus fréquente de morbidité chez les hommes vieillissants. L'évaluation des symptômes urinaires bas et les troubles qui y sont associés sont des facteurs importants pour la prise en charge. Le score IPSS, le score de qualité de vie en rapport avec les symptômes urinaires sont pratiqués pour quantifier la sévérité des troubles urinaires bas. Objectif. Trouver la corrélation entre le volume de la prostate et les symptômes urinaires bas sur la base du score IPSS chez les patients atteints d'HBP histologique. Méthodes. Il s'agissait d'une étude rétrospective de mars 2020 à mars 2021 à l’hôpital Baptiste de Nkwen. Un total de 45 patients ont été inclus, âgés de 40 à 90 ans, avec une confirmation histologique de l'HBP, un IPSS et un volume prostatique documentés. Les données ont été analysées à l'aide du logiciel SPSS version 26.0 et la valeur p < 0,05 a été considérée comme statistiquement significative. Résultats. L'âge moyen était de 69,89 ± 7,526 ans, allant de 40 à 90 ans. La plupart des patients présentaient des symptômes modérés (66,7 %) avec une valeur IPSS moyenne de 17,84 ± 5,661. Il y avait une corrélation significativement positive modérée entre le volume de la prostate et l'IPSS (r = 0,0410, p = 0,006) et aucune corrélation significative entre le volume de la prostate et la qualité de vie. Conclusion. Cette étude a montré qu'il existe une corrélation significative entre le volume de la prostate et le score IPSS dû à l'HBP et aucune corrélation significative entre le score de qualité de vie dû aux symptômes urinaires bas et le volume prostatique calculé par échographie transrectale.

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Author Biographies

Tagang Titus Ngwa-Ebogo, Department of Clinical Sciences, Faculty of Health Sciences, The University of Bamenda, Cameron

Department of Clinical Sciences, Faculty of Health Sciences, The University of Bamenda,   Cameron

Rosine Guylene Sena, Nkwen Baptist Hospital, Bamenda, North West Region, Cameroon

Nkwen Baptist Hospital, Bamenda, North West Region, Cameroon

Bih Kinomia Awanchiri , Nkwen Baptist Hospital, Bamenda, North West Region, Cameroon

Nkwen Baptist Hospital, Bamenda, North West Region, Cameroon

Seraphin Pindi, Department of Clinical Sciences, Faculty of Health Sciences, The University of Bamenda, Cameron

Department of Clinical Sciences, Faculty of Health Sciences, The University of Bamenda,   Cameron

Liekeh Maraitte Ntih, Nkwen Baptist Hospital, Bamenda, North West Region, Cameroon

Nkwen Baptist Hospital, Bamenda, North West Region, Cameroon

Richie Nzinga, Department of Clinical Sciences, Faculty of Health Sciences, The University of Bamenda, Cameron

Department of Clinical Sciences, Faculty of Health Sciences, The University of Bamenda,   Cameron

Fru Forbuzshi Angwafo III, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Cameroon

Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Cameroon

How to Cite
Ngwa-Ebogo, T. T., Sena, R. G., Awanchiri , B. K., Pindi, S., Ntih, L. M., Nzinga, R., & Angwafo III, F. F. (2023). Correlation Between Prostate Volume and IPSS Score in Patients with Histologic Benign Prostate Hypertrophy. HEALTH SCIENCES AND DISEASE, 24(8). https://doi.org/10.5281/hsd.v24i8.4687
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Francis JC, Swain A. Prostate organogenesis. Cold Spring Harb Perspect Med. 2018;8(7)
  2. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148–51.
  3. Lu SH, Chen CS. Natural history and epidemiology of benign prostatic hyperplasia. Formos J Surg. 2014;47(6):207–10.
  4. Verhamme KMC, Dieleman JP, Bleumink GS, Sturkenboom MCJM. Incidence and Prevalence of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Primary Care - The Triumph Project. Eur Urol. 2002;46(4):323-8.
  5. Barry MJ, Fowler FJ, O’leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol. 2017;197(2S).
  6. Ojewola RW, Oridota ES, Balogun OS, Alabi TO, Ajayi AI, Olajide TA, et al. Prevalence of clinical benign prostatic hyperplasia amongst community-dwelling men in a South-Western Nigerian rural setting: A cross-sectional study. Afr J Urol. 2017;23(2):109–15.
  7. Park HJ, Won JEJ, Sorsaburu S, Rivera PD, Lee SW. Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Talalafil. World J Mens Health. 2013;31(3):193.
  8. Napalkov P. Maisonneuve P, Boyle P. Worldwide pattern of prevalence and mortality from benign prostatic hyperplasia. Urology 1995;46(3):41-6.
  9. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J Urol. 2011;185(5):1793– 803.
  10. Kuritzky L. Role of primary care clinicians in the diagnosis and treatment of LUTS and BPH. Rev Urol. 2004;6:S53-9